Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

PTCT - PTC Therapeutics, Inc. Последние новости | Finranks

Home

/

PTCT

P

PTC Therapeutics, Inc. (PTCT)

NMS – Цена в реальном времени. Валюта: USD

72.64

-1.06 (-1.44%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

79.00

+6.36 (8.76%)

После закрытия: Aug 12, 2026, 4:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Top 3 Health Care Stocks You'll Regret Missing This Quarter

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Видео

No Data

There is no data to display

Пресс-релизы

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.